Why did Amgen change its independent accountants?

The filing states that Arthur Andersen LLP was dismissed and PricewaterhouseCoopers LLP was appointed as the new independent public accountants. While the filing doesn't specify the exact reasons or any disagreements, such changes in auditors are often routine or strategic decisions made by a company's board and audit committee. Investors should monitor future communications for any further clarification, though often these changes are not due to reported accounting issues.

Were there any problems with the previous auditor, Arthur Andersen LLP?

According to the filing, Arthur Andersen LLP's reports on Amgen's financial statements for the past two fiscal years did not contain any adverse opinion, disclaimer of opinion, or qualification or modification of opinion. Furthermore, there were no disagreements or reportable events between Amgen and Arthur Andersen LLP during the past two fiscal years or any subsequent interim period. This suggests the change was not prompted by identified accounting disputes or significant audit issues.

What is the significance of changing accounting firms for investors?

A change in auditor can be significant for investors. It may signal a desire for a fresh perspective on financial reporting, a strategic alignment with a different firm's expertise, or potential underlying issues that prompted the change. While this filing indicates no direct disputes, investors should pay close attention to PricewaterhouseCoopers' future audit reports and any commentary they might provide on Amgen's financial practices and internal controls.

When did this change become effective?

The event date cited in the filing is January 25, 1999, which is when the decision regarding the change in accountant was made and approved by the Board of Directors. The filing itself was made on February 1, 1999.

AMGN 8-K SEC Disclosure

Summary

This 8-K filing by Amgen Inc. on February 1, 1999, reports on events occurring on January 25, 1999. The core of the filing pertains to a "Change in Accountant" where Arthur Andersen LLP was dismissed, and PricewaterhouseCoopers LLP was appointed as Amgen's new independent public accountants. This change in auditors is a significant event for investors as it can signal potential shifts in financial reporting scrutiny or strategic directions. While the filing does not detail specific disagreements or issues with Arthur Andersen, the transition to a new firm warrants attention. Investors should monitor future financial statements and audit reports from PricewaterhouseCoopers for any new insights or potential areas of focus. Further details within the filing confirm that the change in accountant was approved by the Board of Directors. The report also indicates that Arthur Andersen's reports on the financial statements for the past two fiscal years did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified regarding uncertainty, deficiency, or inconsistency. This suggests a change driven by factors other than identified accounting irregularities.

Key Highlights

1Amgen Inc. has appointed PricewaterhouseCoopers LLP as its new independent public accountants, replacing Arthur Andersen LLP.
2The change in independent auditors was approved by Amgen's Board of Directors.
3Arthur Andersen LLP's reports for the past two fiscal years contained no adverse opinions or disclaimers.
4There were no disagreements or reportable events with Arthur Andersen LLP during the past two fiscal years or in any subsequent interim period.
5This filing is made under Item 4 of Form 8-K, specifically addressing the "Change in Accountant" event.
6The decision represents a significant governance change regarding the company's external audit function.

AMGEN INC 8-K Report (Feb 1, 1999)

Summary

Key Highlights

Frequently Asked Questions